Citadel Advisors’s Benitec Biopharma BNTC Stock Holding History

Citadel Advisors’s Portfolio BNTC Stock Details BNTC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.09M	Sell	81,466 -90,256	-53%	-$1.07M	﹤0.01%	7994
2026 Q1	$1.83M	Buy	171,722 +154,142	+877%	+$1.78M	﹤0.01%	6263
2025 Q4	$237K	Buy	+17,580	New	+$243K	﹤0.01%	10678
2024 Q4	–	Sell	-14,244	Closed	-$131K	–	14530
2024 Q3	$131K	Buy	+14,244	New	+$127K	﹤0.01%	10743
2023 Q4	–	Sell	-69,515	Closed	-$210K	–	14296
2023 Q3	$210K	Buy	+69,515	New	+$216K	﹤0.01%	9808
2022 Q3	–	Sell	-2,939	Closed	-$58K	–	12636
2022 Q2	$58K	Buy	+2,939	New	+$68.3K	﹤0.01%	11839
2021 Q3	–	Sell	-1,201	Closed	-$87K	–	13815
2021 Q2	$87K	Sell	1,201 -167	-12%	-$13.1K	﹤0.01%	13025
2021 Q1	$120K	Buy	+1,368	New	+$93K	﹤0.01%	12293
2019 Q3	–	Sell	-128	Closed	-$24K	–	9164
2019 Q2	$24K	Buy	+128	New	+$51.9K	﹤0.01%	8913
2018 Q4	–	Sell	-47	Closed	-$30K	–	9112
2018 Q3	$30K	Buy	+47	New	+$32.1K	﹤0.01%	8930
2017 Q1	–	Sell	-63	Closed	-$25K	–	7441
2016 Q4	$25K	Buy	+63	New	+$24K	﹤0.01%	7032

Other funds holding BNTC

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SAM

Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

IAM

Infinitum Asset Management Fort Lauderdale, Florida $983M AUM 26.53% 1-Year Est. Return

Citadel Advisors's BNTC Position: Q2 2026 in Review

Citadel Advisors reduced its Benitec Biopharma (BNTC) stake by 53% in Q2 2026, selling an estimated $1.07M and leaving 81,466 shares worth $1.09M. The position accounts for ﹤0.01% of the portfolio, ranked #7994.

Citadel Advisors first reported a position in BNTC in Q4 2016 and has held it in 11 quarters since. The position peaked at $1.83M in Q1 2026. 87 funds tracked by Wall St. Rank hold BNTC as of Q2 2026.

Citadel Advisors held 81,466 shares of Benitec Biopharma worth $1.09M as of Q2 2026.
Citadel Advisors sold 90,256 Benitec Biopharma shares in Q2 2026, an estimated $1.07M.
Benitec Biopharma made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #7994 holding.
Citadel Advisors first reported a position in Benitec Biopharma in Q4 2016 and has held it in 11 quarters since.
Citadel Advisors's Benitec Biopharma position peaked at $1.83M in Q1 2026.
87 funds tracked by Wall St. Rank held Benitec Biopharma as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.